Urinary Marker for Oxidative Stress in Human Cisplatin- Induced Renal Injury

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2005 by Hamamatsu University.
Recruitment status was  Recruiting
Information provided by:
Hamamatsu University
ClinicalTrials.gov Identifier:
First received: April 3, 2006
Last updated: November 6, 2006
Last verified: April 2005
We previously reported early measurement of urinary MDA might be a useful marker for the prediction of CDDP-induced renal damage in rat. The purpose of this clinical study is to test whether the changes of human urinary excretion of MDA, and can be used as early biomarker for the prediction of development of CDDP-induced ARF.

Kidney Failure

Study Type: Observational
Study Design: Observational Model: Natural History
Time Perspective: Longitudinal

Further study details as provided by Hamamatsu University:


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hospitalized patients have neck cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00310739

Contact: Takayuki Tsuji, MD +81-53-435-2261 tsu@hama-med.ac.jp

Hamamatsu University School of Medicine Recruiting
Hamamatsu, Shizuoka, Japan, 431-3192
Contact: Takayuki Tsuji, MD    +81-53-435-2261    tsu@hama-med.ac.jp   
Sponsors and Collaborators
Hamamatsu University
Principal Investigator: Takayuki Tsuji, MD Hamamatsu University
  More Information

ClinicalTrials.gov Identifier: NCT00310739     History of Changes
Other Study ID Numbers: 16-50 
Study First Received: April 3, 2006
Last Updated: November 6, 2006
Health Authority: Japan: Institutional Review Board

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on May 26, 2016